Peripheral T-cell lymphoma: pharmacotherapy overview

Peripheral T-cell lymphomas are a heterogeneous group of aggressive diseases associated with poor outcome. The current aim in peripheral T-cell lymphoma is to enhance the understanding of the disease, in order to aid the development of more effective treatments. There has been a plethora of targeted treatments available for T-cell lymphomas. In this review article, we will present an overview of some of these novel agents, including the antifolate (pralatrexate), histone deacetylase inhibitors (vorinostat, belinostat and romidepsin), proteasome inhibitors (bortezomib and carfilzomib), mTOR inhibitors (temsirolimus and everolimus), monoclonal antibodies (alemtuzumab, brentuximab vedotin, zanolimumab, anti-CXCR4 and antiCCR4), immunomodulatory agent (lenalidomide), nucleoside analogs (gemcitabine, clofarabine, forodesine and pentostatin), and fusion toxin (denileukin diftitox).